Skip to main content
. 2023 Feb 8;15:44. doi: 10.1007/s40820-023-01018-4

Fig. 16.

Fig. 16

Schematic illustration of a fabrication of the nanosonosensitizer P/M@CasMTH1 and b US-triggered genome-editing-augmented SDT for tumor treatment. c Confocal laser scanning microscopy (CLSM) images of A549-EGFP cells after different treatments. d Western blot analysis of the MTH1 expression in A549 cells after different treatments. e NGS analysis of indel percentage in P/M@CasMTH1 or P/M@CasMTH1 + US treatment groups. f Viability of A549 cells after SDT or combined therapy treatment. g Digital photographs of dissected tumors in different treatment groups [181].

Copyright 2021, Wiley–VCH GmbH